{"title": "Preformulation study of a Cuban pentavalent DPT-HB-Hib vaccine, Heberpenta\u00ae-L", "author": "N\u00e9stor S Exp\u00f3sito-Raya; Yayr\u00ed C Prieto-Correa; Mabel Izquierdo-L\u00f3pez; Zoe Nu\u0144ez-Lamothe; Soraya Piloto-D\u00edaz; Yamila Mart\u00ednez-Cuellar; Makis Torres-Toledo; Annette Pereira-Sanabria; Rub\u00e9n L\u00f3pez-Edghill; Jose L Marcelo-Sainz; Amarilys Rodriguez-Arrebato; Mar\u00eda de los A Denis-Cruz; Yanet Alderete-Avalos; Anaelsi Chacon-Molina; Eduardo Mart\u00ednez-D\u00edaz", "url": null, "hostname": null, "description": null, "sitename": "Biotecnolog\u00eda Aplicada", "date": "1999-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "2020, Number 1\nBiotecnol Apl 2020; 37 (1)\nPreformulation study of a Cuban pentavalent DPT-HB-Hib vaccine, Heberpenta\u00ae-L\n[ ](addFavorito.php?idArt=103949&idPub=9742)\nExp\u00f3sito-Raya NS, Prieto-Correa YC, Izquierdo-L\u00f3pez M, Nu\u0144ez-Lamothe Z, Piloto-D\u00edaz S, Mart\u00ednez-Cuellar Y, Torres-Toledo M, Pereira-Sanabria A, L\u00f3pez-Edghill R, Marcelo-Sainz JL, Rodriguez-Arrebato A, Denis-Cruz MA, Alderete-Avalos Y, Chacon-Molina A, Mart\u00ednez-D\u00edaz E\nLanguage: English\nReferences: 37\nPage: 1201-1209\nPDF size: 391.46 Kb.\nABSTRACT\nThe development of combined vaccines is a very useful project for all the advantages that this type of vaccine provides. However, complexities in its execution due to their technological challenges make difficult its development. In this sense, the pentavalent vaccine (DPT-HB-Hib), branded as Heberpenta\u00ae, has been produced in Cuba containing five antigens: diphtherial and tetanus anatoxins, whole cells of Bordetella pertussis, recombinant hepatitis B virus surface antigen and the synthetic polysaccharide (polyribosyl ribitol phosphate, PRP) of Haemophilus influenzae conjugated with tetanus anatoxin (PRP-T). A pre-formulation study was carried out using a mixture of adjuvants defining the optimum absorption time for each antigen. Three lots formulated at a pilot scale with a defined technology were studied using different physical-chemical and biological tests. The technology for the formulation of the pentavalent vaccine produced in Cuba was defined according to these results, which must later undergo stability studies and preclinical and clinical studies.\nREFERENCES\nSkibinski DAG, Baudner BC, Singh M, O\u2019Hagan DT. Combination vaccines. J Global Infect Dis. 2011;3(1):63-72.\nMarshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496-500.\nKalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25:507-12.\nWeston WM, Klein NP. Kinrix: A new combination DTaPIPV vaccine for children aged 46 years. Expert Rev Vaccines. 2008;7:1309-20.\nBogaerts H. The future of childhood immunizations: Examining the European experience. Am J Manag Care. 2003;9:S30-6.\nPetre J, Hauser P, inventors; Glaxo- SmithKline Biologicals S.A., assignee. Combined vaccines comprising hepatitis B surface antigens and other vaccines. EP 0835663B1. 1993 May 15.\nJones LTS, Peek LJ, Power J, Markham A, Yazzie B, Middaugh CR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J Biol Chem. 2005;280(14):13406- 14.\nMatheis W, Zott A, Schwanig M. The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine. 2001;20(1-2):67-73.\nRamon G. Floculation dans un \u00e9lange neutre de toxin-antitoxine dipht\u00e9riques. CR Soc Biol. 1922;86:6.\nWorld Health Organization. Manual for the Production and Control of Vaccines: Tetanus Toxoid. Geneva: WHO; 1978.\nGonz\u00e1lez-Griego A, Alerm A, Vega I, Ram\u00edrez V, Salgado A, Vingut JL. Cuantificaci\u00f3n del ant\u00edgeno de superficie del VHB (HBsAg) en muestras biol\u00f3gicas con fines asistenciales y preparativos. Biotecnol Apl. 1993;10(2):10.\nBritish Pharmacopoeia. London: Her Majesty\u2019s Stationery Office; 2004.\nUnited States Pharmacopoeia 30. National Formulary 25. United States Pharmacopoeia Convention; Inc.: Rockville, MD; 2007.\nPPO 4.09.064.92. Determinaci\u00f3n de la concentraci\u00f3n de i\u00f3n aluminio por Complejometr\u00eda. La Habana: CIGB; 1999.\nCIGB. PPO 4.09.062.92. Espectrofotometr\u00eda m\u00e9todo utilizado por el fabricante (CIGB) para la cuantificaci\u00f3n de Tiomersal en las vacunas monovalentes y combinadas. La Habana: CIGB; 1992.\nBioCen. PNO 07.154, Determinaci\u00f3n de la toxicidad espec\u00edfica de las anatoxinas dift\u00e9rica y tet\u00e1nica en la vacuna pentavalente DPT-HB-Hib, Heberpenta-L. La Habana: BioCen; 2009.\nBioCen. PNO 07.155, Determinaci\u00f3n de la toxicidad espec\u00edfica de la Bordetella pertussis en la vacuna pentavalente DPT-HB-Hib, Heberpenta-L. La Habana: BioCen; 2009.\nGonz\u00e1lez P, Mart\u00ednez S, Ram\u00edrez JC, Dom\u00ednguez F, D\u00edaz Y, Ram\u00edrez U, et al. Vacuna antidift\u00e9rica-tet\u00e1nica y antidift\u00e9ricatet\u00e1nica- pertussis: evaluaci\u00f3n del producto final. VacciMonitor. 1999;8(2):8-12.\nCIGB. PPO.4.09.093.04. Procedimiento para la determinaci\u00f3n de la identidad del AgsHB utilizando el sistema ELISA en vacunas. La Habana: CIGB; 2013.\nCIGB. PPO.4.09.041.03. Procedimiento para la determinaci\u00f3n de la identidad del PRP-T utilizando el m\u00e9todo de inmunoidentificaci\u00f3n por Latex en vacunas. La Habana: CIGB; 2008.\nFitzgerald EA. Overview of the methods for potency testing of diphtheria and tetanus toxoids in the United States. In: Manclark CR (ed). Proceedings of an Informal Consultation on the World Health Organization Requirements for Diphtheria, Tetanus, Pertussis and Combined Vaccines. Department of Health and Human Services, United States Public Health Service. Bethesda, MD, DHHS Publication No. (FDA) 91-1174; 1991. pp 61-4.\nFinney D J. Probit Analysis. 3rd edition. New York: Cambridge University Press; 1971.\nWorld Health Organization. Manual of laboratory methods for testing of vaccines used in the WHO Expanded Programme on Inmunization. Global programme for vaccines and inmunization. Vaccine supply and quality. Assay for testing the potency of whole cell pertussis vaccines in monovalent or combined form. Geneva: WHO; 1997.\nCIGB. PPO 4.09.060.92. Edici\u00f3n 09. Procedimiento establecido para la determinaci\u00f3n de la potencia in vivo de la vacuna la hepatitis B recombinante y vacunas combinadas que contengan como componente activo el AgsHB. La Habana: CIGB; 2008.\nCIGB. PPO 4.09.037.03. Procedimiento para la determinaci\u00f3n de la inmunogenicidad del componente PRP-T en vacunas. La Habana: CIGB; 2013.\nBaylor NW, Egan W, Richman P. Aluminum salts in vaccines--US perspective. Vaccine. 2002; 20 Suppl 3:S18-23.\nKool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol. 2012;61:927-34.\nGupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminium and calcium compounds. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press; 1995. p. 229-48.\nWalls RS. Eosinophil response to alum adjuvants: Involvement of T cells in nonantigen- dependent mechanisms. Proc Soc Exp Biol Med. 1977;156:431-5.\nRappuoli R. New and improved vaccines against diphteria and tetanus. In: Woodrow GC, Levine MM. (eds), New Generation Vaccines. New York: Marcel Dekker; 1990. pp. 251.\nLatham WC, Bent DF, Levine L. Tetanus toxin production in the absence of protein. Appl Environ Microbiol. 1962;10(2): 146-52.\nOrganizaci\u00f3n Mundial de la Salud. Gu\u00eda de la OMS sobre los requisitos de las pr\u00e1cticas adecuadas de fabricaci\u00f3n (PAF). Segunda parte: Validaci\u00f3n. WHO/ VSQ/97.02. Geneva: OMS; 1998.\nLiu J, Feldkamp JL, White JL, Hem SL. Adsorption of phosphate by aluminum hydroxycarbonate. J Pharm Sci. 1984;73:1355-8.\nBleam WF, Pfeffer PE, Goldberg S, Taylor RW, Dudley RA. 31p solid-state nuclear magnetic resonance study of phosphate adsorption at the boehmite/aqueous solution interface. Langmuir. 1991;7:1702-12.\nIyer S, Robinett RS, HogenEsch H, Hem SL. Mechanism of adsorption of hepatitis B surface antigen by aluminum hydroxide adjuvant. Vaccine. 2004;22:1475-9.\nSturgess AW, Rush K, Charbonneau RJ, Lee JI, West DJ, Sitrin RD, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerisation of PRP in the presence of aluminium hydroxide. Vaccine, 1999;17(9-10):1169-78.\nGilchrist M Jr. Bordetella. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadomy HJ (eds). Manual of clinical microbiology, 5th ed. Washington DC: American Society for Microbiology; 1991. pp. 471-7.", "language": null, "image": null, "pagetype": null, "links": ["https://www.medigraphic.com/", "resumen.cgi?IDARTICULO=103949", "#", "https://www.medigraphic.com/cgi-bin/new/publicacionesI.cgi?IDREVISTA=281", "https://www.medigraphic.com/cgi-bin/new/contenidoI.cgi?IDPUBLICACION=9742", "https://www.medigraphic.com/cgi-bin/new/publicacionesI.cgi?IDREVISTA=281", "#", "https://www.medigraphic.com/cgi-bin/new/informacion.cgi?IDREVISTA=281", "https://www.medigraphic.com/cgi-bin/new/directorio.cgi?IDREVISTA=281", "#", "https://www.medigraphic.com/cgi-bin/new/instrucciones.cgi?IDREVISTA=281", "https://www.medigraphic.com/", "https://www.medigraphic.com/", "https://www.medigraphic.com/cgi-bin/new/medigraphic.cgi", "#", "#", "#", "#", "addFavorito.php?idArt=103949&idPub=9742", "https://www.medigraphic.com/pdfs/biotecapl/ba-2020/ba201a.pdf", "#", null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null, null]}